Adagene Inc. (ADAG)

Etorro trading 970x250

About Adagene Inc.

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. Its products include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase Ib clinical trials for the treatment advanced solid tumors and non-Hodgkin’s lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in preclinical stage used in the treatment of cancers; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of metastatic solid tumors. The company was founded in 2011 and is headquartered in Suzhou, China. Address: Building C14, Suzhou, China, 25125

Adagene Inc. News and around…

Latest news about Adagene Inc. (ADAG) common stock and company :

Adagene Enters Oversold Territory (ADAG)
01 Oct, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Sum Up The Pieces: PGJ Could Be Worth $67
30 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Golden Dragon China ETF (PGJ), we found that the implied analyst target price for the ETF based upon its underlying holdings is $67.47 per unit.

Adagene to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference
02 Sep, 2021 FinancialContent
Adagene Reports Financial Results for the Six Months Ended June 30, 2021 and Provides Corporate Updates
26 Aug, 2021 FinancialContent
Adagene Inks Third Cancer Trial Collaboration With Merck
19 Aug, 2021 FinancialContent

Adagene Inc(NASDAQ: ADAG) has entered into athird clinical trial collaborationand supply agreement withMerck ...

The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
19 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106, in Combination Therapy with KEYTRUDA® (pembrolizumab)
19 Aug, 2021 FinancialContent

Collaboration to evaluate NEObody™ product candidate, ADG106, in combination with KEYTRUDA® for patients with advanced or metastatic solid and/or hematological malignancies

Adagene Announces Appointment of Interim Chief Medical Officer and New Members of Scientific and Strategic Advisory Board
12 Aug, 2021 FinancialContent

- Global immuno-oncology experts bring decades of experience to advance company’s transformative research and development pipeline -

62 Biggest Movers From Yesterday
28 Jul, 2021 FinancialContent

Gainers Intrusion Inc. (NASDAQ: INTZ) shares surged 52.1% to settle at $5.14 on Tuesday. Intrusion recently issued ...

74 Biggest Movers From Yesterday
27 Jul, 2021 FinancialContent

Gainers Bit Digital, Inc. (NASDAQ: BTBT) shares jumped 109.7% to close at $8.87 on Monday after the company announced it entered ...

Adagene To Test Its Anti-CTLA-4 Monoclonal Antibodies In Combination With Keytruda In Solid Tumors
22 Jul, 2021 FinancialContent

Adagene Inc(NASDAQ: ADAG) has entered into aclinical trial collaboration and supply agreementwithMerck & ...

Adagene Announces Clinical Trial Collaboration With Merck to Advance Two Anti-CTLA-4 Monoclonal Antibody Programs (ADG116 and ADG126) in Combination Therapy with KEYTRUDA® (pembrolizumab)
22 Jul, 2021 FinancialContent

Two global clinical studies to evaluate NEObody™ product candidate, ADG116, and SAFEbody™ product candidate, ADG126, in combination with KEYTRUDA® (pembrolizumab) for patients with advanced/metastatic solid tumors

China’s U.S. IPO Queue to Shrink Amid Regulatory Crackdown
13 Jul, 2021 Yahoo! Finance

(Bloomberg) -- China’s crackdown on U.S. initial public offerings by its companies has put its burgeoning pipeline of potential listings at risk.A medical data company, a fitness app and an e-commerce platform have, in the past week, postponed plans to go public in the U.S., as Beijing cracks down on tech and data-heavy firms listing stateside. There are about 70 other private firms based in Hong Kong and China set to go public in New York, according to data compiled by Bloomberg.The broadened s

20 Chinese Companies Listed on NYSE/NASDAQ/AMEX
09 Jul, 2021 Yahoo! Finance

In this article, we discuss the 20 Chinese companies listed on NYSE/NASDAQ/AMEX. If you want to skip our detailed analysis of these companies, go directly to the 5 Chinese Companies Listed on NYSE/NASDAQ/AMEX. The trade tension between the United States and China over the past few years has dominated headlines around the world, fueling speculation […]

Adagene Announces Authorization of Share Repurchase Program up to US$20 Million
07 Jul, 2021 FinancialContent
Benzinga's Top Ratings Upgrades, Downgrades For June 25, 2021
25 Jun, 2021 FinancialContent

Upgrades According to Argus Research, the prior rating for Duke Energy Corp (NYSE:DUK) was changed from Hold to Buy. ...

Top Chinese Companies on NASDAQ
16 Jun, 2021 Yahoo! Finance

In this article, we discuss the top Chinese companies on NASDAQ. If you want to skip our detailed analysis of these companies, go directly to the Top 5 Chinese Companies on NASDAQ. Chinese companies have taken the American stock market by storm in recent years as Beijing gradually opens up to investments from the outside […]

Adagene Announces Inclusion in FTSE Russell Indexes
16 Jun, 2021 FinancialContent
44 Biggest Movers From Friday
01 Jun, 2021 FinancialContent

Gainers Vertex Energy, Inc. (NASDAQ: VTNR) shares jumped 95.7% to close at $7.81 on continued momentum after the company announced ...

38 Stocks Moving In Friday's Mid-Day Session
28 May, 2021 FinancialContent

Gainers Vertex Energy, Inc. (NASDAQ: VTNR) shares surged 48.6% to $5.93 on continued momentum after the company announced it will ...

Adagene to Present at Upcoming Investor Conferences
25 May, 2021 FinancialContent
Adagene Presents Clinical Data from NEObody™ Program, ADG106, Anti-CD137 Agonist, in an Abstract at ASCO 2021 Annual Meeting
19 May, 2021 FinancialContent
12 Health Care Stocks Moving In Wednesday's Intraday Session
19 May, 2021 FinancialContent

Gainers Lianluo Smart (NASDAQ:LLIT) stock rose 35.13% to $10.0 during Wednesday's regular session. Lianluo ...

The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
12 May, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings
11 May, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs
07 May, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex
20 Apr, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug
13 Apr, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Adagene Presents Preclinical Data from Lead SAFEbody™ Program, ADG126, at the American Association for Cancer Research (AACR) Annual Meeting 2021
13 Apr, 2021 Yahoo! Finance

SAN FRANCISCO and SUZHOU, China, April 13, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced updated preclinical data from its lead SAFEbody™ program, ADG126, are being presented at the American Association for Cancer Research (AACR) Annual Meeting 2021. “There is a critical unmet need for new anti-CTLA-4 therapies, and we are encouraged by the data generated to date, which demonstrate ADG126 has the potential to overcome the severe immune-mediated adverse reactions associated with the class,” said Peter Luo, Ph.D., Co-founder, Chief Executive Officer and Chairman of Adagene. “By leveraging our SAFEbody platform technology, designed to precisely and very efficiently mask the antibody binding interface and activate specifically within the tumor microenvironment, our preclinical data continues to highlight the opportunity to effectively deliver treatment; ADG126 has demonstrated superior systemic safety profile at efficacious dose levels with a significantly enlarged therapeutic index (TI). Our ongoing global Phase 1 trial is expected to provide clinical validation for our SAFEbody platform and our SAFEbody product candidate, ADG126. We have successfully finished DLT evaluation of 3 patients at 0.1 mg/kg of ADG126 and remain on track to report topline safety and efficacy data in the second half of 2021.” A copy of the poster presentation, entitled “A Novel Anti-CTLA-4 Checkpoint Inhibitor Prodrug to Address On-target Off-tumor Toxicity for Cancer Immunotherapy,” is available on the AACR website and is also available for download via our website (https://www.adagene.com/). The data presented show: Notable Findings: ADG126 demonstrated an impressive safety margin while maintaining its potent antitumor activity.Unique Epitope with Broad Species Cross-Reactivity: ADG126 targets a conserved epitope of CTLA-4 with broad species cross-reactivity and is an activatable prodrug for tumor suppression in multiple syngeneic mouse models in single and combination therapies.Differentiated Mechanism of Action: Although the activated ADG126 is softer in blocking CTLA-4 binding with its ligands than ipilimumab, the activated ADG126 exhibited more potent antibody dependent cellular cytotoxicity (ADCC) in the tumor microenvironment.Intra-Tumoral Treg Depletion: Treg cells in tumor tissues exhibited higher CTLA-4 expression than in peripheral tissues and were efficiently depleted upon treatment with ADG126 in the immune-competent mouse syngeneic colon tumor model.Human T-Cell Activation in Vitro: Activated ADG126 potently enhanced T-cell activation, measured by IL-2 secretion, whereas the masked ADG126 did not.In Vivo Monotherapy Antitumor Activity: ADG126 exhibited potent antitumor activity as a single agent in different immune-competent syngeneic mouse tumor models.In Vivo Combination Antitumor Activity: ADG126 combined synergistically with other IO agents, such as anti-PD-1 antibody, to inhibit tumor growth in vivo. Combination therapy significantly slowed tumor growth and caused complete regression in 50% of Lewis lung cancer mouse models.Safety and Tolerability: ADG126 was well tolerated in animals suggesting the potential for high therapeutic index. The highest non-severely toxic dose (HNSTD) was determined to be 200 mg/kg/dose, which is one of the highest reported HNSTD for anti-CTLA-4 antibodies. About ADG126ADG126 is a fully human antagonistic mAb targeting a novel epitope of CTLA-4 and has been shown to specifically deplete regulatory T-cells in tumors. ADG126 is Adagene’s lead SAFEbody™ product candidate. The SAFEbody technology, developed using Adagene’s AI-powered platform, enables binding of an antibody to a specific target only after conditional activation of the antibody in target tissues. In preclinical studies, ADG126 was well tolerated in cynomolgus monkeys and demonstrated an encouraging antitumor response in multiple immune-competent mouse tumor models in a dose-dependent manner both as a single agent and in combination with anti-PD-1 and other therapies. Unlike anti-PD-1/PD-L1 check point inhibitors, anti-CTLA-4 is known for its dose-dependent clinical response in single and combination therapies, which is severely limited by the narrow therapeutic window available to current anti-CTLA-4 therapies. The large safety margin shown by ADG126 GLP toxicology studies of up to 200 mg/kg in targeting CTLA-4 will make it possible to dose patients for their optimal clinical benefits in single and combination therapies. About AdageneAdagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by its proprietary DPL platform, composed of NEObody, SAFEbody, and POWERbody technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science. For more information, please visit: https://investor.adagene.com. Safe Harbor StatementThis press release contains forward-looking statements, including statements regarding data from the ADG126 preclinical studies and Phase I clinical trial, the potential implications of clinical data for patients, and Adagene’s advancement of, and anticipated clinical development, regulatory milestones and commercialization of ADG126. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to Adagene’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Adagene’s drug candidates; Adagene’s ability to achieve commercial success for its drug candidates, if approved; Adagene’s ability to obtain and maintain protection of intellectual property for its technology and drugs; Adagene’s reliance on third parties to conduct drug development, manufacturing and other services; Adagene’s limited operating history and Adagene’s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; Adagene’s ability to enter into additional collaboration agreements beyond its existing strategic partnerships or collaborations, and the impact of the COVID-19 pandemic on Adagene’s clinical development, commercial and other operations, as well as those risks more fully discussed in the “Risk Factors” section in Adagene’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Adagene, and Adagene undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. Investors Contact:Raymond TamAdagene86-512-8777-3626ir@adagene.com Bruce MackleLifeSci Advisors646-889-1200bmackle@lifesciadvisors.com Media Contact:Annie Starr6 Degrees973-768-2170astarr@6degreespr.com

The Daily Biotech Pulse: Negative Regulatory Tidings For Provention Bio, Celcuity Soars On In-licensing Deal, 2 IPOs
09 Apr, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Adagene Inc. (ADAG) is a NASDAQ Common Stock listed in , ,

970x250